Search results
Results from the WOW.Com Content Network
While the stock appears pricey on a forward price-to-earnings (P/E) basis, trading at 39 times next year's analyst estimates, it only has a price/earnings-to-growth ratio (PEG ratio) of 0.6 given ...
From a valuation perspective, Lilly trades at a forward price-to-earnings (P/E) ratio of 37 times 2025 analyst estimates but has a price/earnings-to-growth (PEG) ratio of under 0.4. PEGs below 1 ...
The good news for investors is that for 2025, overall guidance is looking strong. Lilly is projecting between $58 billion and $61 billion in sales, which is mostly higher than the $58.4 billion ...
The drugs, known as GLP-1s, have brought in $50 billion in revenue for Novo Nordisk year to date alone, but the high prices ($1,349 for Wegovy and $968 for Ozempic) have put them out of reach for ...
The monthly list prices for the injectables have been at or over $1,000; Sanders has repeatedly linked to a study at Yale University that found the drugs can be manufactured for less than $5 per ...
Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.CEO Bob Bradway shared a peek at phase II results of the ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
If the company's GLP-1 treatment, referred to as just VK2735 for now, obtains approval, this already hot stock could become an even more coveted investment to own.